Ankylosing Spondylitis Treatment Market (2026 - 2035)

ID: MRFR/HC/10650-HCR 200 Pages Rahul Gotadki Last Updated: November 04, 2026
Ankylosing Spondylitis Treatment Market Research Report By Treatment Type (Non-Steroidal Anti-Inflammatory Drugs, Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, Analgesics, Disease Modifying Anti-Rheumatic Drugs), By Route of Administration (Oral, Injectable, Topical), By Patient Type (Adults, Pediatric), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2026 To 2035
Ankylosing Spondylitis Treatment Market
Market Size
Forecast Period2026-2035
CAGR (2026-2035)6.9%
2025 Market SizeUSD 6.75 Billion
2035 Market SizeUSD 13.13 Billion
Key Players
Novartis AG
AbbVie Inc.
Amgen Inc.
Johnson & Johnson
UCB S.A.
Pfizer Inc.
Opportunities
  • Biosimilar-Led Access in Emerging Markets
  • Next-Generation Mechanisms for Refractory Disease
  • Real-World Data and Outcomes-Based Contracting
  1. 1 Market Summary | |
    1. 1.1 Study Assumptions & Market Definition | |
    2. 1.2 Scope of the Study | |
    3. 1.3 Research Methodology | |
  2. 2 Key Report Takeaways | |
    1. 2.1 By Drug Class | |
    2. 2.2 By Route of Administration | |
    3. 2.3 By Distribution Channel | |
    4. 2.4 By Region | |
  3. 3 Market Size and Forecast (2021–2035) | |
    1. 3.1 Historical Market Size (2021–2025) | |
    2. 3.2 Current & Forecast Market Size (2026–2035) | |
    3. 3.3 Year-over-Year Growth Analysis | |
  4. 4 Driver Impact Analysis | |
    1. 4.1 IL-17 and Dual IL-17A/F Label Expansion | |
    2. 4.2 Oral JAK Inhibitor Adoption | |
    3. 4.3 Asia Pacific Reimbursement Expansion | |
    4. 4.4 Guideline-Backed NSAID Repositioning | |
    5. 4.5 Medicare Part D Out-of-Pocket Cap | |
    6. 4.6 Specialty and Online Home Delivery | |
  5. 5 Restraints Impact Analysis | |
    1. 5.1 Biosimilar Price Erosion in TNF Inhibitors | |
    2. 5.2 Prolonged Diagnostic Delay | |
    3. 5.3 Medicare Negotiated Pricing | |
    4. 5.4 Limited Coverage in Emerging Economies | |
    5. 5.5 JAK Inhibitor Safety Warnings | |
  6. 6 Opportunities | |
    1. 6.1 Biosimilar-Led Access in Emerging Markets | |
    2. 6.2 Next-Generation Mechanisms for Refractory Disease | |
    3. 6.3 Real-World Data and Outcomes-Based Contracting | |
    4. 6.4 Earlier Diagnosis Through Imaging and Referral Tools | |
    5. 6.5 Self-Injection Device Lifecycle Management | |
    6. 6.6 Industry Value Chain Analysis | |
    7. 6.7 Porter's Five Forces Analysis | |
  7. 7 Regional Market Share and Country-Level Analysis | |
    1. 7.1 North America | | |
      1. 7.1.1 United States | | |
      2. 7.1.2 Canada | | |
      3. 7.1.3 Mexico | |
    2. 7.2 Europe | | |
      1. 7.2.1 Germany | | |
      2. 7.2.2 United Kingdom | | |
      3. 7.2.3 France | | |
      4. 7.2.4 Italy | | |
      5. 7.2.5 Spain | | |
      6. 7.2.6 Rest of Europe | |
    3. 7.3 Asia Pacific | | |
      1. 7.3.1 China | | |
      2. 7.3.2 Japan | | |
      3. 7.3.3 India | | |
      4. 7.3.4 South Korea | | |
      5. 7.3.5 Australia | | |
      6. 7.3.6 Rest of Asia Pacific | |
    4. 7.4 Middle East and Africa | | |
      1. 7.4.1 GCC | | |
      2. 7.4.2 South Africa | | |
      3. 7.4.3 Rest of Middle East and Africa | |
    5. 7.5 South America | | |
      1. 7.5.1 Brazil | | |
      2. 7.5.2 Argentina | | |
      3. 7.5.3 Rest of South America | |
  8. 8 Future Outlook (2026–2035) | |
    1. 8.1 AI-Assisted Imaging and Earlier Diagnosis | |
    2. 8.2 Price-Reset Economics | |
    3. 8.3 Oral and Multi-Target Pipelines | |
    4. 8.4 Home-Based Care and Digital Adherence | |
  9. 9 Segmentation Analysis | |
    1. 9.1 By Drug Class | | |
      1. 9.1.1 NSAIDs | | |
      2. 9.1.2 TNF Inhibitors | | |
      3. 9.1.3 IL-17 Inhibitors | | |
      4. 9.1.4 JAK Inhibitors | | |
      5. 9.1.5 Biosimilars | | |
      6. 9.1.6 Others | |
    2. 9.2 By Route of Administration | | |
      1. 9.2.1 Oral | | |
      2. 9.2.2 Subcutaneous | | |
      3. 9.2.3 Intravenous | |
    3. 9.3 By Distribution Channel | | |
      1. 9.3.1 Hospital Pharmacies | | |
      2. 9.3.2 Retail Pharmacies | | |
      3. 9.3.3 Online Pharmacies | |
  10. 10 Competitive Landscape | |
    1. 10.1 Market Concentration Analysis (2025) | |
    2. 10.2 Competitive Benchmarking Matrix | |
    3. 10.3 Company Profiles | | |
      1. 10.3.1 Novartis AG | | |
      2. 10.3.2 AbbVie Inc. | | |
      3. 10.3.3 Amgen Inc. | | |
      4. 10.3.4 Johnson & Johnson | | |
      5. 10.3.5 UCB S.A. | | |
      6. 10.3.6 Pfizer Inc. | | |
      7. 10.3.7 Eli Lilly and Company | | |
      8. 10.3.8 Celltrion Inc. | | |
      9. 10.3.9 Sandoz Group AG | | |
      10. 10.3.10 Samsung Bioepis | | |
      11. 10.3.11 Merck & Co., Inc. | |
  11. 11 Recent News & Developments | |
  12. 12 Report Scope and Methodology | |
  13. 13 Detailed Sources and Citations | |
  14. 14 Frequently Asked Questions (FAQs) | | LIST OF TABLES | |
  15. TABLE 1 Global Market Size & Forecast, by Revenue (USD Billion), 2021–2035 | |
  16. TABLE 2 Year-over-Year Growth Analysis, 2021–2035 | |
  17. TABLE 3 Driver Impact Analysis, 2026–2035 | |
  18. TABLE 4 Restraints Impact Analysis, 2026–2035 | |
  19. TABLE 5 Global Market Size, by Region, 2021–2035 (USD Billion) | |
  20. TABLE 6 North America Market Size, by Country, 2021–2035 (USD Billion) | |
  21. TABLE 7 Europe Market Size, by Country, 2021–2035 (USD Billion) | |
  22. TABLE 8 Asia Pacific Market Size, by Country, 2021–2035 (USD Billion) | |
  23. TABLE 9 Middle East and Africa Market Size, by Country, 2021–2035 (USD Billion) | |
  24. TABLE 10 South America Market Size, by Country, 2021–2035 (USD Billion) | |
  25. TABLE 11 Global Market Size, by Drug Class, 2021–2035 (USD Billion) | |
  26. TABLE 12 Global Market Size, by Route of Administration, 2021–2035 (USD Billion) | |
  27. TABLE 13 Global Market Size, by Distribution Channel, 2021–2035 (USD Billion) | |
  28. TABLE 14 Competitive Benchmarking Matrix, 2025 | |
  29. TABLE 15 Recent Developments & Strategic Announcements, 2023–2025 | |
  30. TABLE 16 Report Scope and Methodology | |
  31. TABLE 17 Detailed Sources and Citations | | LIST OF FIGURES | |
  32. FIGURE 1 Market Dynamics Overview — Drivers, Restraints, and Opportunities | |
  33. FIGURE 2 Industry Value Chain Analysis | |
  34. FIGURE 3 Porter's Five Forces Analysis | |
  35. FIGURE 4 Global Market Size Trend, 2021–2035 (USD Billion) | |
  36. FIGURE 5 Market Share by Drug Class, 2025 (%) | |
  37. FIGURE 6 Market Share by Route of Administration, 2025 (%) | |
  38. FIGURE 7 Market Share by Distribution Channel, 2025 (%) | |
  39. FIGURE 8 Market Share by Region, 2025 (%) | |
  40. FIGURE 9 Country-Level Revenue Share within Each Region, 2025 (%) | |
  41. FIGURE 10 Competitive Landscape — Estimated Revenue Share Ranges, 2025

Segmentation Quick Reference

DimensionSub-SegmentsDominant SegmentFastest Growing Segment
By Drug ClassNSAIDs, TNF Inhibitors, IL-17 Inhibitors, JAK Inhibitors, Biosimilars, OthersTNF Inhibitors (50.4% share)NSAIDs (8.3% CAGR)
By Route of AdministrationOral, Subcutaneous, IntravenousSubcutaneous (55.4% share)Oral (8.5% CAGR)
By Distribution ChannelHospital Pharmacies, Retail Pharmacies, Online PharmaciesHospital Pharmacies (46.9% share)Online Pharmacies (8.0% CAGR)
By RegionNorth America, Europe, Asia Pacific, Middle East and Africa, South AmericaNorth America (41.8% share)Asia Pacific (8.6% CAGR)

Market Segmentation Overview

By Drug Class

Sub-SegmentKey Trend
NSAIDsContinuous COX-2 therapy repositioned as structure-modifying
TNF InhibitorsVolume steady, net price falling under biosimilar pressure
IL-17 InhibitorsShare gains in biologic-naïve and switcher patients
JAK InhibitorsOral option after TNF failure, limited by boxed warnings
BiosimilarsFormulary-mandated switching from originator TNF brands
OthersCorticosteroids, conventional DMARDs, and pipeline agents

TNF Inhibitors lead the drug class mix at a 50.4% share because adalimumab and etanercept still anchor most first biologic starts. NSAIDs grow fastest at an 8.3% CAGR as guidelines keep them first-line and continuous celecoxib dosing gains credibility for slowing spinal fusion. IL-17 Inhibitors take incremental share from TNF agents, especially where bimekizumab is positioned for patients needing stronger radiographic control.

By Route of Administration

Sub-SegmentKey Trend
OralJAK inhibitors and long-term NSAIDs drive tablet growth
Sub-cutaneousAutoinjectors and high-concentration pens dominate home use
IntravenousNiche use for infusion-preferring or reaction-prone patients

Subcutaneous administration leads with a 55.4% share since nearly every major biologic is self-injected at home. Oral delivery grows fastest at an 8.5% CAGR as JAK inhibitors move into post-TNF lines and payers accept tablet regimens with simpler logistics. Intravenous use persists mainly through biosimilar infliximab and IV secukinumab in infusion centres.

By Distribution Channel

Sub-SegmentKey Trend
Hospital PharmaciesBiologic initiation, infusions, and safety monitoring
Retail PharmaciesNSAID and oral small-molecule dispensing
Online PharmaciesCold-chain home delivery and copay assistance

Hospital Pharmacies hold a 46.9% share because biologic initiation, infusion chairs, and adverse-event monitoring sit inside health systems. Online Pharmacies grow fastest at an 8.0% CAGR as PBM-owned specialty arms bundle home delivery, nurse training, and refill reminders for working-age patients. Retail Pharmacies remain essential for NSAIDs and oral agents but continue to lose complex biologics to specialist channels.

Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.